Diag-Nose.io
Diag-Nose.io is a biotechnology company focused on eliminating respiratory diseases through AI-powered precision diagnostics and drug discovery. Founded in 2020 by specialists in ENT, bioengineering, and entrepreneurship, the company leverages its RhinoMAP platform, which combines nasal microsampling, proteomics, and AI (machine learning) to analyze airway biology. This approach aims to provide faster, more accurate diagnoses and personalized treatments for conditions like asthma, COPD, and sinusitis, moving beyond traditional trial-and-error methods. Diag-Nose.io has secured seed funding and grants to advance its research and clinical studies, with a mission to improve a billion lives by enabling precise differentiation of respiratory disorders and the prescription of correct therapies. The company is developing products such as the ABEL Microsampler for nasal liquid biopsy and NEBULA, a database for respiratory diseases.
Diag-Nose.io
Diag-Nose.io is a biotechnology company focused on eliminating respiratory diseases through AI-powered precision diagnostics and drug discovery. Founded in 2020 by specialists in ENT, bioengineering, and entrepreneurship, the company leverages its RhinoMAP platform, which combines nasal microsampling, proteomics, and AI (machine learning) to analyze airway biology. This approach aims to provide faster, more accurate diagnoses and personalized treatments for conditions like asthma, COPD, and sinusitis, moving beyond traditional trial-and-error methods. Diag-Nose.io has secured seed funding and grants to advance its research and clinical studies, with a mission to improve a billion lives by enabling precise differentiation of respiratory disorders and the prescription of correct therapies. The company is developing products such as the ABEL Microsampler for nasal liquid biopsy and NEBULA, a database for respiratory diseases.